Your browser is no longer supported. Please, upgrade your browser.
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.00 Insider Own0.30% Shs Outstand67.36M Perf Week-12.14%
Market Cap2.76B Forward P/E- EPS next Y-3.49 Insider Trans-4.88% Shs Float66.37M Perf Month-25.55%
Income-116.00M PEG- EPS next Q-0.75 Inst Own73.70% Short Float15.38% Perf Quarter-54.33%
Sales90.70M P/S30.43 EPS this Y26.00% Inst Trans-2.52% Short Ratio4.34 Perf Half Y7.80%
Book/sh6.32 P/B5.49 EPS next Y-4.50% ROA-20.20% Target Price53.57 Perf Year49.12%
Cash/sh5.05 P/C6.87 EPS next 5Y- ROE-31.00% 52W Range21.41 - 99.95 Perf YTD-50.55%
Dividend- P/FCF- EPS past 5Y0.70% ROI-34.30% 52W High-65.31% Beta1.96
Dividend %- Quick Ratio7.20 Sales past 5Y123.40% Gross Margin- 52W Low61.93% ATR3.36
Employees235 Current Ratio7.20 Sales Q/Q-7.30% Oper. Margin- RSI (14)31.88 Volatility8.52% 7.83%
OptionableYes Debt/Eq0.00 EPS Q/Q-38.60% Profit Margin- Rel Volume2.88 Prev Close40.98
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 BMO Payout- Avg Volume2.35M Price34.67
Recom2.80 SMA20-17.58% SMA50-27.47% SMA200-19.66% Volume6,775,505 Change-15.40%
Apr-16-21Initiated Goldman Sell $20
Mar-22-21Initiated Credit Suisse Outperform $58
Mar-01-21Downgrade Barclays Overweight → Equal Weight $46
Feb-26-21Downgrade Truist Buy → Hold $45
Jan-19-21Downgrade Morgan Stanley Equal-Weight → Underweight $64 → $45
Jan-07-21Downgrade Raymond James Outperform → Mkt Perform
Dec-10-20Upgrade Wells Fargo Equal Weight → Overweight $69
Nov-03-20Initiated Robert W. Baird Underperform $14
Jun-18-20Resumed SunTrust Buy $45
Feb-21-20Initiated Wells Fargo Equal Weight $28
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Apr-16-21 03:51PM  
03:31PM  
02:39PM  
02:05PM  
07:05AM  
06:30AM  
Apr-07-21 10:58AM  
Apr-02-21 08:06AM  
Mar-29-21 05:52AM  
Mar-27-21 11:31AM  
Mar-11-21 12:06PM  
Mar-09-21 11:52AM  
Mar-06-21 10:12AM  
Mar-04-21 11:36PM  
04:08PM  
Feb-27-21 09:23AM  
Feb-26-21 09:04AM  
Feb-25-21 01:00PM  
07:00AM  
05:45AM  
Feb-23-21 02:29PM  
Feb-20-21 09:03AM  
Feb-18-21 04:02PM  
Feb-17-21 06:30AM  
Feb-12-21 05:45PM  
Feb-10-21 04:42PM  
Feb-08-21 08:00AM  
Feb-05-21 06:10AM  
Feb-04-21 05:45PM  
Jan-26-21 06:30AM  
Jan-25-21 05:45PM  
06:01AM  
Jan-24-21 07:10AM  
Jan-20-21 11:31PM  
10:30PM  
Jan-19-21 04:01PM  
Jan-18-21 08:41AM  
Jan-15-21 06:12PM  
05:45PM  
Jan-14-21 03:11PM  
Jan-12-21 01:24PM  
Jan-11-21 12:20PM  
08:02AM  
06:05AM  
06:02AM  
06:00AM  
Jan-08-21 09:01AM  
Jan-07-21 04:24PM  
08:42AM  
Jan-06-21 11:00AM  
Jan-05-21 06:23AM  
Jan-04-21 04:05PM  
09:27AM  
06:09AM  
Dec-31-20 11:43PM  
Dec-29-20 12:27PM  
Dec-24-20 11:10AM  
Dec-23-20 07:29PM  
01:30PM  
Dec-22-20 09:58AM  
Dec-21-20 04:24PM  
12:12PM  
Dec-17-20 04:05PM  
Dec-16-20 06:47PM  
07:35AM  
Dec-14-20 01:58PM  
Dec-10-20 02:03PM  
12:47PM  
11:40AM  
09:44AM  
07:42AM  
Dec-09-20 04:01PM  
11:27AM  
11:06AM  
Dec-08-20 03:41PM  
Dec-07-20 11:41AM  
Dec-05-20 11:32AM  
10:00AM  
Nov-10-20 04:01PM  
05:41AM  
Nov-09-20 04:05PM  
09:00AM  
Nov-07-20 09:06AM  
Nov-06-20 03:30PM  
11:24AM  
Nov-05-20 05:25PM  
04:15PM  
04:02PM  
Nov-02-20 10:31AM  
Oct-29-20 04:01PM  
Oct-21-20 10:23AM  
Oct-13-20 09:45AM  
Oct-12-20 09:45AM  
Oct-10-20 09:55AM  
Oct-07-20 10:04AM  
Oct-06-20 07:45PM  
Sep-30-20 06:45AM  
Sep-18-20 06:43PM  
Sep-11-20 07:00AM  
Sep-05-20 11:32AM  
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hopfield JessicaDirectorMar 03Buy45.515,800263,97022,700Mar 05 04:13 PM
MULLEN JAMES CCEOMar 02Buy46.2725,0001,156,80035,000Mar 04 04:17 PM
Collins CynthiaCEOFeb 09Sale66.651,26284,11243,760Feb 10 04:26 PM
ROBERTSON MICHELLEChief Financial OfficerJan 12Sale78.271,568122,72718,432Jan 13 04:11 PM
Albright CharlesEVP/Chief Scientific OfficerDec 15Option Exercise16.5110,000165,10034,907Dec 17 06:58 PM
Albright CharlesEVP/Chief Scientific OfficerDec 15Sale63.2210,000632,15624,907Dec 17 06:58 PM
Albright CharlesEVP/Chief Scientific OfficerDec 09Option Exercise16.5110,000165,10034,907Dec 11 04:14 PM
Albright CharlesEVP/Chief Scientific OfficerDec 09Sale45.0010,000450,00024,907Dec 11 04:14 PM
Albright CharlesEVP/Chief Scientific OfficerDec 07Option Exercise16.5120,000330,20044,907Dec 08 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerDec 07Sale40.0220,000800,40024,907Dec 08 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerNov 09Sale31.212287,11624,907Nov 10 04:13 PM
Albright CharlesEVP/Chief Scientific OfficerOct 15Sale31.393,00094,17025,135Oct 16 04:38 PM
Collins CynthiaCEOAug 20Sale36.661,97672,44045,022Aug 21 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerAug 17Option Exercise16.5110,000165,10038,135Aug 19 04:44 PM
Albright CharlesEVP/Chief Scientific OfficerAug 17Sale35.2910,000352,90028,135Aug 19 04:44 PM
Albright CharlesEVP/Chief Scientific OfficerAug 07Sale34.992388,32828,135Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerAug 06Option Exercise16.5110,000165,10038,373Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerAug 06Sale37.4710,000374,70028,373Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerJul 15Sale32.223,00096,66028,373Jul 17 05:32 PM
Albright CharlesEVP/Chief Scientific OfficerMay 06Sale25.281513,81731,373May 08 04:17 PM